410 related articles for article (PubMed ID: 17555455)
1. Incorporation of fibrin molecules containing fibrinopeptide A alters clot ultrastructure and decreases permeability.
Flood VH; Nagaswami C; Chernysh IN; Al-Mondhiry HA; Weisel JW; Farrell DH
Br J Haematol; 2007 Jul; 138(1):117-24. PubMed ID: 17555455
[TBL] [Abstract][Full Text] [Related]
2. The fibrinogen Aalpha R16C mutation results in fibrinolytic resistance.
Flood VH; Al-Mondhiry HA; Farrell DH
Br J Haematol; 2006 Jul; 134(2):220-6. PubMed ID: 16846481
[TBL] [Abstract][Full Text] [Related]
3. Fibrinogen Nový Jicín and Praha II: cases of hereditary Aalpha 16 Arg-->Cys and Aalpha 16 Arg-->His dysfibrinogenemia.
Kotlín R; Chytilová M; Suttnar J; Riedel T; Salaj P; Blatný J; Santrůcek J; Klener P; Dyr JE
Thromb Res; 2007; 121(1):75-84. PubMed ID: 17408725
[TBL] [Abstract][Full Text] [Related]
4. Homophenotypic Aalpha R16H fibrinogen (Kingsport): uniquely altered polymerization associated with slower fibrinopeptide A than fibrinopeptide B release.
Galanakis DK; Neerman-Arbez M; Scheiner T; Henschen A; Hubbs D; Nagaswami C; Weisel JW
Blood Coagul Fibrinolysis; 2007 Dec; 18(8):731-7. PubMed ID: 17982313
[TBL] [Abstract][Full Text] [Related]
5. The sequence of cleavage of fibrinopeptides from fibrinogen is important for protofibril formation and enhancement of lateral aggregation in fibrin clots.
Weisel JW; Veklich Y; Gorkun O
J Mol Biol; 1993 Jul; 232(1):285-97. PubMed ID: 8331664
[TBL] [Abstract][Full Text] [Related]
6. Abnormal fibrinogen with an Aα 16Arg → Cys substitution is associated with multiple cerebral infarctions.
Luo M; Wei A; Xiang L; Yan J; Liao L; Deng X; Deng D; Cheng P; Lin F
J Thromb Thrombolysis; 2018 Oct; 46(3):409-419. PubMed ID: 29869737
[TBL] [Abstract][Full Text] [Related]
7. Decreased plasmin resistance by clots of a homophenotypic Aalpha R 16H fibrinogen (Kingsport, slower fibrinopeptide A than fibrinopeptide B release).
Galanakis DK; Neerman-Arbez M; Kudryk B; Henschen A
Blood Coagul Fibrinolysis; 2010 Mar; 21(2):135-9. PubMed ID: 20019599
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of fibrinogen Bicêtre II: a gamma 308 Asn-->Lys mutation located near the fibrin D:D interaction sites.
Marchi RC; Carvajal Z; Boyer-Neumann C; Anglés-Cano E; Weisel JW
Blood Coagul Fibrinolysis; 2006 Apr; 17(3):193-201. PubMed ID: 16575257
[TBL] [Abstract][Full Text] [Related]
9. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis.
Kwasny-Krochin B; Gluszko P; Undas A
Thromb Res; 2010 Jul; 126(1):e11-6. PubMed ID: 20471669
[TBL] [Abstract][Full Text] [Related]
10. A novel natural mutation AαPhe98Ile in the fibrinogen coiled-coil affects fibrinogen function.
Riedelová-Reicheltová Z; Kotlín R; Suttnar J; Geierová V; Riedel T; Májek P; Dyr JE
Thromb Haemost; 2014 Jan; 111(1):79-87. PubMed ID: 24108601
[TBL] [Abstract][Full Text] [Related]
11. Fibrinogen Guarenas, an abnormal fibrinogen with an Aalpha-chain truncation due to a nonsense mutation at Aalpha 467 Glu (GAA)-->stop (TAA).
Marchi R; Carvajal Z; Meyer M; Soria J; Ruiz-Saez A; Arocha-Piñango CL; Weisel JW
Thromb Res; 2006; 118(5):637-50. PubMed ID: 16406498
[TBL] [Abstract][Full Text] [Related]
12. Altered fibrin clot properties in patients on long-term haemodialysis: relation to cardiovascular mortality.
Undas A; Kolarz M; Kopeć G; Tracz W
Nephrol Dial Transplant; 2008 Jun; 23(6):2010-5. PubMed ID: 18156458
[TBL] [Abstract][Full Text] [Related]
13. Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function.
Standeven KF; Grant PJ; Carter AM; Scheiner T; Weisel JW; Ariëns RA
Circulation; 2003 May; 107(18):2326-30. PubMed ID: 12707238
[TBL] [Abstract][Full Text] [Related]
14. A novel mutation in the fibrinogen Aα chain (Gly13Arg, fibrinogen Nanning) causes congenital dysfibrinogenemia associated with defective peptide A release.
Yan J; Luo M; Cheng P; Liao L; Deng X; Deng D; Lin F
Int J Hematol; 2017 Apr; 105(4):506-514. PubMed ID: 27933517
[TBL] [Abstract][Full Text] [Related]
15. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
[TBL] [Abstract][Full Text] [Related]
16. Dysfibrinogenemia in childhood: two cases of congenital dysfibrinogens.
Kotlín R; Blažek B; Suttnar J; Malý M; Kvasnička J; Dyr JE
Blood Coagul Fibrinolysis; 2010 Oct; 21(7):640-8. PubMed ID: 20829681
[TBL] [Abstract][Full Text] [Related]
17. FXIII polymorphisms, fibrin clot structure and thrombotic risk.
Kobbervig C; Williams E
Biophys Chem; 2004 Dec; 112(2-3):223-8. PubMed ID: 15572253
[TBL] [Abstract][Full Text] [Related]
18. Effect of ioxaglate--an ionic low osmolar contrast medium--on fibrin polymerization in vitro.
Brass O; Belleville J; Sabattier V; Corot C
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):689-97. PubMed ID: 8292718
[TBL] [Abstract][Full Text] [Related]
19. Fibrinogen Caracas V, an abnormal fibrinogen with an Aalpha 532 Ser-->Cys substitution associated with thrombosis.
Marchi R; Lundberg U; Grimbergen J; Koopman J; Torres A; de Bosch NB; Haverkate F; Arocha Piñango CL
Thromb Haemost; 2000 Aug; 84(2):263-70. PubMed ID: 10959699
[TBL] [Abstract][Full Text] [Related]
20. In vitro fibrin clot formation and fibrinolysis using heterozygous plasma fibrinogen from gammaAsn319, Asp320 deletion dysfibrinogen, Otsu I.
Terasawa F; Kani S; Hongo M; Okumura N
Thromb Res; 2006; 118(5):651-61. PubMed ID: 16412498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
